Detalhe da pesquisa
1.
Lisocabtagene maraleucel for second-line relapsed or refractory large B-cell lymphoma: patient-reported outcomes from the PILOT study.
Haematologica
; 109(3): 857-866, 2024 Mar 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-37646670
2.
Impact of bortezomib-based versus lenalidomide maintenance therapy on outcomes of patients with high-risk multiple myeloma.
Cancer
; 129(14): 2179-2191, 2023 07 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-37021929
3.
The mutational landscape in chronic myelomonocytic leukemia and its impact on allogeneic hematopoietic cell transplantation outcomes: a Center for Blood and Marrow Transplantation Research (CIBMTR) analysis.
Haematologica
; 108(1): 150-160, 2023 01 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-35443559
4.
Association between the choice of the conditioning regimen and outcomes of allogeneic hematopoietic cell transplantation for myelofibrosis.
Haematologica
; 108(7): 1900-1908, 2023 Jul 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-36779595
5.
Lisocabtagene maraleucel as second-line therapy in adults with relapsed or refractory large B-cell lymphoma who were not intended for haematopoietic stem cell transplantation (PILOT): an open-label, phase 2 study.
Lancet Oncol
; 23(8): 1066-1077, 2022 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-35839786
6.
African Americans with translocation t(11;14) have superior survival after autologous hematopoietic cell transplantation for multiple myeloma in comparison with Whites in the United States.
Cancer
; 127(1): 82-92, 2021 01 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-32966625
7.
The Role of Donor Lymphocyte Infusion (DLI) in Post-Hematopoietic Cell Transplant (HCT) Relapse for Chronic Myeloid Leukemia (CML) in the Tyrosine Kinase Inhibitor (TKI) Era.
Biol Blood Marrow Transplant
; 26(6): 1137-1143, 2020 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-32062061
8.
Maintenance Tyrosine Kinase Inhibitors Following Allogeneic Hematopoietic Stem Cell Transplantation for Chronic Myelogenous Leukemia: A Center for International Blood and Marrow Transplant Research Study.
Biol Blood Marrow Transplant
; 26(3): 472-479, 2020 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-31669399
9.
A Personalized Prediction Model for Outcomes after Allogeneic Hematopoietic Cell Transplant in Patients with Myelodysplastic Syndromes.
Biol Blood Marrow Transplant
; 26(11): 2139-2146, 2020 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-32781289
10.
Risk Factors for Graft-versus-Host Disease in Haploidentical Hematopoietic Cell Transplantation Using Post-Transplant Cyclophosphamide.
Biol Blood Marrow Transplant
; 26(8): 1459-1468, 2020 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-32434056
11.
Endothelial cell function and endothelial-related disorders following haematopoietic cell transplantation.
Br J Haematol
; 190(4): 508-519, 2020 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-32319084
12.
Novel role of prostate apoptosis response-4 tumor suppressor in B-cell chronic lymphocytic leukemia.
Blood
; 131(26): 2943-2954, 2018 06 28.
Artigo
em Inglês
| MEDLINE | ID: mdl-29695515
13.
Impact of cytogenetic abnormalities on outcomes of adult Philadelphia-negative acute lymphoblastic leukemia after allogeneic hematopoietic stem cell transplantation: a study by the Acute Leukemia Working Committee of the Center for International Blood and Marrow Transplant Research.
Haematologica
; 105(5): 1329-1338, 2020 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-31558669
14.
Prognostic impact of Philadelphia chromosome in mixed phenotype acute leukemia (MPAL): A cancer registry analysis on real-world outcome.
Am J Hematol
; 95(9): 1015-1021, 2020 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-32419244
15.
Chronic Lymphocytic Leukemia-Derived IL-10 Suppresses Antitumor Immunity.
J Immunol
; 200(12): 4180-4189, 2018 06 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-29712773
16.
Sensitizing the interdisciplinary team to desensitizations: An alemtuzumab case report.
J Oncol Pharm Pract
; 26(3): 742-746, 2020 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-31390960
17.
Revised International Staging System Is Predictive and Prognostic for Early Relapse (<24 months) after Autologous Transplantation for Newly Diagnosed Multiple Myeloma.
Biol Blood Marrow Transplant
; 25(4): 683-688, 2019 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-30579965
18.
Autologous Hematopoietic Stem Cell Transplantation for Male Germ Cell Tumors: Improved Outcomes Over 3 Decades.
Biol Blood Marrow Transplant
; 25(6): 1099-1106, 2019 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-30794931
19.
Impact of T Cell Dose on Outcome of T Cell-Replete HLA-Matched Allogeneic Peripheral Blood Stem Cell Transplantation.
Biol Blood Marrow Transplant
; 25(9): 1875-1883, 2019 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-31085303
20.
Non-Graft-versus-Host Disease Ocular Complications after Hematopoietic Cell Transplantation: Expert Review from the Late Effects and Quality of Life Working Committee of the Center for International Blood and Marrow Transplant Research and the Transplant Complications Working Party of the European Society for Blood and Marrow Transplantation.
Biol Blood Marrow Transplant
; 25(5): e145-e154, 2019 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-30521975